Breast Cancer
Jan 17, 2022
Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this...
Jan 17, 2022
MicroRNAs (miRNAs) act as oncogenes or tumor suppressors by suppressing the expression of target genes, some of which are engaged in angiogenic signaling pathways directly or indirectly. Tumor develop...
Jan 10, 2022
Research on the role of insulin resistance (IR) in breast cancer risk in premenopausal women is scarce. We aimed to investigate the relationship between IR and the development of breast cancer in prem...
Jan 03, 2022
SIN3A, a scaffold protein has regulatory functions in tumor biology. Through its Paired amphipathic helix (PAH2) domain, SIN3A interacts with PHF12 (PF1), a protein with SIN3 interaction domain (SID) ...
Dec 27, 2021
To clarify the effect of postmastectomy radiotherapy (PMRT) on pTN breast cancer patients with different molecular subtypes.We retrospectively analyzed the data of 5442 patients with pTN breast cancer...
Dec 27, 2021
The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level...
Dec 15, 2021
In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positive/HER2-neg...
Dec 15, 2021
According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with ER-positi...
Dec 15, 2021
Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy follow...
Dec 15, 2021
A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial, it provid...
Dec 15, 2021
Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows no benefit...
Dec 15, 2021
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of...
Dec 15, 2021
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings in ER-posi...
Dec 15, 2021
Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...
Dec 15, 2021
Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...
Dec 15, 2021
The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR-posit...
Dec 15, 2021
Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient...
Dec 15, 2021
Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast cancer (TN...
Dec 15, 2021
In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression can be combined with tamoxifen or an aromatase inhibitor. A meta-analysis of 4 randomized controlled t...
Dec 15, 2021
Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A meta-analysis based on data of 18,203 participants now demonstrates anthracycline/taxane to reduce the ...